Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19

J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e293-e295. doi: 10.1097/MPH.0000000000002014.

Abstract

Relapse of infection due to SARS-CoV-2 has been rarely described and there is little guidance regarding the management of such cases in immunocompromised hosts. We present a case of an adolescent female with B-cell acute lymphoblastic leukemia hospitalized multiple times for symptomatic SARS-CoV-2 infection who was safely treated with 2 courses of remdesivir (RDV) and has had no additional readmissions to date. Though additional studies are needed to confirm the safety and efficacy of an additional course of RDV in the setting of relapsed or prolonged severe COVID-19, our observations suggest that a second course of RDV may be considered.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives*
  • Adenosine Monophosphate / therapeutic use
  • Adolescent
  • Alanine / analogs & derivatives*
  • Alanine / therapeutic use
  • Antiviral Agents / therapeutic use*
  • COVID-19 / complications
  • COVID-19 / diagnosis
  • COVID-19 / immunology
  • COVID-19 Drug Treatment*
  • Disease Management
  • Female
  • Hospitalization
  • Humans
  • Immunocompromised Host*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • SARS-CoV-2 / isolation & purification

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine